Form 8-K REVIVA PHARMACEUTICALS For: Dec 16
Reviva Pharmaceuticals Holdings, Inc. (RVPH)
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
RVPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVPH alerts
High impacting Reviva Pharmaceuticals Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
RVPH
News
- Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and WarrantsGlobeNewswire
- Reviva Announces Proposed Public OfferingGlobeNewswire
- Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia [Yahoo! Finance]Yahoo! Finance
- Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in SchizophreniaGlobeNewswire
- Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]Yahoo! Finance
RVPH
Earnings
- 11/14/24 - Miss
RVPH
Sec Filings
- 12/20/24 - Form SCHEDULE
- 12/18/24 - Form 424B5
- 12/16/24 - Form 424B5
- RVPH's page on the SEC website